Comparing dexmedetomidine and midazolam for kidney protection in septic ICU patients
Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit
PHASE1 · Minia University · NCT05903963
This study tests whether the sedative dexmedetomidine can better protect the kidneys of intubated septic patients in the ICU compared to midazolam.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Minia University (other) |
| Locations | 1 site (Minya) |
| Trial ID | NCT05903963 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of dexmedetomidine compared to midazolam as a sedative in septic patients who are intubated and mechanically ventilated in the intensive care unit. The focus is on assessing renal protection during sedation, which is crucial for patients experiencing renal failure. The study aims to determine which sedative may offer better outcomes for kidney function in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are intubated and mechanically ventilated patients aged 18 to 80 who are experiencing septic conditions.
Not a fit: Patients with pre-existing renal pathologies or serious central nervous system conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved kidney protection strategies for critically ill septic patients.
How similar studies have performed: While there is ongoing research in sedation practices for ICU patients, this specific comparison of dexmedetomidine and midazolam for renal protection is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age (18-80) years old. sex:both male and female. * intubated and mechanically ventilated patients. Exclusion Criteria: * 1.Patient's relatives refusal. 2. burns as admitting diagnoses. 3.patients with any renal pathology(such as chronic glomerulonephritis, pyelonephritis and diabetic nephropathy). 4. pregnancy or lactation. 5. serious central nervous system pathology (acute stroke, uncontrolled seizures, severe dementia). 6. acute hepatitis or severe liver disease (Child-Pugh class C). 7. unstable angina or acute myocardial infarction, left ventricular ejection fraction less than 30%, heart rate less than 50/min, second- or third-degree heart block, or systolic blood pressure less than 90 mm Hg despite continuous infusions of 2 vasopressors before the start of study drug infusion.
Where this trial is running
Minya
- Marlin Zarif Shehata — Minya, Egypt (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Renal Failure